Live tape
Top 8, mentions 7d7,576META2,272 mentions▲ +0.06GOOGL1,514 mentions▲ +0.02NVDA811 mentions▲ +0.09MUSE666 mentions▲ +0.07MSFT610 mentions▲ +0.06SPY576 mentions▲ +0.05QQQ565 mentions▲ +0.08TSLA562 mentions▲ +0.06

Equity · Healthcare

TNGX

Tango Therapeutics, Inc. · NasdaqGM

$24.91 +1.12% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close) · Sep 25, 2026
Price · Chart
Our own end-of-day closes 37 sessions
$35 $20 30 Jun 25 Sep

The line runs $31.25 on 30 June through $24.91 on 25 September, on a scale from $20 to $35. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView

The chart above plots the price of TNGX over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 37 sessions over that window: $31.25 on 30 June 2026 through $24.91 on 25 September 2026.

Market cap $4.2B
52-week range $6.91 – $32.91
Avg volume 257.3K

Finazon · prior-day close, indicative (IEX-derived, not the official close) · valuation computed from SEC EDGAR filings · as of Sep 25, 2026

TNGX insider trades

SEC Form 4

TNGX has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 3 November 2025.

Date Insider Type Shares Value
23 Oct 2025 Third Rock Ventures IV, L.P. Sell 477,401 $4.85M
25 Sep 2025 Third Rock Ventures IV, L.P. Sell 500,000 $4.01M
16 Sep 2025 Third Rock Ventures IV, L.P. Sell 363,541 $2.56M
08 Sep 2025 Third Rock Ventures IV, L.P. Sell 86,459 $609K
05 Sep 2025 Third Rock Ventures IV, L.P. Sell 642,906 $4.50M

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
03 Nov 2025 Peters Malte Award 150,000

TNGX reported financials

SEC EDGAR XBRL

TNGX reported revenue of $62.4M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$101.6M.

Figure Reported Period
Revenue $62.4M 31 Dec 2025 fiscal year
Net income −$101.6M 31 Dec 2025 fiscal year
Diluted EPS −$0.87 31 Dec 2025 fiscal year
Total assets $1.1B 30 Jun 2026 at period end
Total equity $1.0B 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

TNGX earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $-0.37 —
31 Mar 2026 Q1 2026 $-0.32 —
31 Dec 2025 FY 2025 $-0.87 $62M
30 Sep 2025 Q3 2025 $0.13 $54M
30 Jun 2025 Q2 2025 $-0.35 $3M
31 Mar 2025 Q1 2025 $-0.36 $5M
31 Dec 2024 FY 2024 $-1.19 $42M
30 Sep 2024 Q3 2024 $-0.27 $12M

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

TNGX institutional holders

SEC Form 13F

10 of the 45 institutional funds we track reported a TNGX position for the quarter ended 30 Jun 2026 — a combined $161.3M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Balyasny Asset Management Trimmed −47.3% shares 2,016,379 $63.0M
Renaissance Technologies New position 748,300 $23.4M
Fisher Asset Management Added +256.0% shares 578,158 $18.1M
Millennium Management Held (±25%) +16.5% shares 496,036 $15.5M
Baker Bros. Advisors New position 333,333 $10.4M
Point72 Asset Management Trimmed −44.1% shares 298,339 $9.3M
Two Sigma Investments Added +39.7% shares 241,783 $7.6M
Citadel Advisors Held (±25%) +0.9% shares 181,059 $5.7M
Marshall Wace New position 174,909 $5.5M
AQR Capital Management Held (±25%) −15.2% shares 91,029 $2.8M

Source: SEC EDGAR 13F filings

TNGX fails-to-deliver

SEC CNS data

On 25 Aug 2026, 1 shares of TNGX failed to deliver (about $25) — the latest of 2 consecutive trading days with recorded fails.

Settlement date Shares failed Notional % of shares out
25 Aug 2026 1 $25 <0.001%
24 Aug 2026 1,764 $42K 0.001%
20 Aug 2026 67 $2K <0.001%

Source: SEC fails-to-deliver (CNS) data